Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients. (November 2013)

• Record Type: Journal Article
• Authors: do Sameiro-Faria, Maria; Ribeiro, Sandra; Rocha-Pereira, Petronila; Fernandes, João; Reis, Flávio; Bronze-da-Rocha, Elsa; Miranda, Vasco; Quintanilha, Alexandre; Costa, Elísio; Belo, Luís; Santos-Silva, Alice
• Is Part Of: Renal failure. Volume 35:Number 10(2013)
• Page Start: 1392
• Page End: 1398
• Publication Date: 2013-11
• Subjects: Chronic renal failure -- Periodicals; Acute renal failure -- Periodicals; Uremia -- Periodicals; 616.614005
• DOI: 10.3109/0886022X.2013.828267
• Languages: English
• ISSNs: 0886-022X

Abstract

<abstract> <title>Abstract</title> <p>The aim of this work was to contribute to a better understanding of the relationship between resistance to recombinant human erythropoietin (rhEPO) therapy and body mass index (BMI) in hemodialysis (HD) patients. We evaluated 191 HD patients and 25 healthy individuals. Complete blood count, reticulocyte count, and circulating levels of ferritin, transferrin, iron, soluble transferrin receptor (sTfR), transferrin saturation, hepcidin, C-reactive protein (CRP), interleukin 6 (IL-6), albumin, and adiponectin were measured in all patients and controls. Non-responder patients (<italic>n</italic> = 16), as compared with responder patients (<italic>n</italic> = 175), showed statistically significant lower BMI values, an enhanced inflammatory and higher adiponectin levels, associated with disturbances in iron metabolism. Analyzing the results according to BMI, we found that underweight patients required higher rhEPO doses than normal, overweight, and obese patients, and a higher percentage of non-responders patients were found within the underweight group of HD patients. Moreover, underweight patients presented lower levels of transferrin and higher levels of adiponectin compared to overweight and obese patients, and lower levels of iron compared with normal weight patients. Multiple regression analysis identified the sTfR, hemoglobin, BMI, and albumin as independent variables associated with rhEPO doses. In conclusion, our work showed that HD patients resistant to rhEPO therapy present a functional iron deficiency and a higher degree of inflammation, despite their lower BMI values and higher levels of adiponectin. Actually, BMI is poorly related with markers of systemic inflammation, such as IL-6 and CRP, while adiponectin works a fairly good indirect marker of adiposity within HD patients.</p> </abstract>